Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1Dermatologic 1CNS 1

Conditions

Sarcoma 6Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Rhabdomyosarcoma 5Prostatic Neoplasms 5Sarcoma, Synovial 3Osteosarcoma 3Neuroectodermal Tumors, Primitive, Peripheral 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Sarcoma, Ewing 2Neoplasm Metastasis 2Lung Neoplasms 2Liposarcoma 2Leiomyosarcoma 2Hemangiosarcoma 2Head and Neck Neoplasms 2Fibrosarcoma 2Zollinger-Ellison Syndrome 1Wilms Tumor 1Uveal Melanoma 1Unspecified Childhood Solid Tumor, Protocol Specific 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Small Cell Lung Carcinoma 1Retinoblastoma 1Paraganglioma 1Pancreatic Neoplasms 1Neurofibrosarcoma 1Neuroendocrine Tumors 1

Interventions

pembrolizumab 6Nivolumab 6Ipilimumab 4Radiotherapy 3talimogene laherparepvec 2budigalimab 2avelumab 2atezolizumab 2Everolimus 2Cyclophosphamide 2zimberelimab 1venetoclax 1vatalanib 1tremelimumab 1temsirolimus 1sapanisertib 1rovalpituzumab tesirine 1poly ICLC 1oblimersen 1lorvotuzumab mertansine 1lanreotide 1glucopyranosyl lipid-A 1fludarabine 1durvalumab 1domatinostat 1cixutumumab 1cemiplimab 1aldesleukin 1Vinorelbine 1Surgical Procedures, Operative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma, Merkel Cell × cixutumumab × Clear all
NCT01204476 2016-07-15

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

National Cancer Institute (NCI)

Phase 1 Completed
27 enrolled
CNSDermatologicEndocrine

Glucagonoma, Insulinoma, Paraganglioma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡